Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Liver Int ; 43(6): 1225-1233, 2023 06.
Article in English | MEDLINE | ID: mdl-37026404

ABSTRACT

INTRODUCTION: Chronic hepatitis C (CHC) is considered an important public health challenge. Traditionally identified risk factors have undergone an epidemiological transition where other risk factors have become the main cause of new infections. OBJECTIVE: To describe risk factors associated to hepatitis C positivity through the evaluation of the epidemiological profile in hepatitis-C high-risk populations. METHODS: Cross-sectional study was conducted as part of an HCV screening program in Mexican population. All participants answered an HCV risk-factor questionnaire and took a rapid test (RT). All patients reactive to the test were subject to HCV PCR (polymerase chain reaction) confirmation. A logistic regression model was used to examine associations between HCV infection and risk factors. RESULTS: The study included 297 631 participants that completed a risk factor questionnaire and underwent an HCV rapid test (RT). In total, 12 840 (4.5%) were reactive to RT and 9257 (3.2% of participants) were confirmed as positives by PCR test. Of these, 72.9% had at least one risk factor and 10.8% were in prison. Most common risk factors were history of acupuncture/tattooing/piercing (21%), intravenous drug use (15%) and high-risk sexual practices (12%). Logistic regressions found that having at least one risk factor increased the probability of having an HCV-positive result by 20% (OR = 1.20, 95% CI: 1.15-1.26), compared to the population without risk factors. CONCLUSIONS: We identified 3.2% of HCV-viremic subjects, all associated with risk factors and older age. Screening and diagnosis of HCV in high-risk populations (including underserved populations) should be more efficient.


Subject(s)
Hepatitis C , Substance Abuse, Intravenous , Humans , Cross-Sectional Studies , Hepatitis C/diagnosis , Hepatitis C/epidemiology , Hepatitis C/drug therapy , Risk Factors , Hepacivirus , Substance Abuse, Intravenous/complications , Prevalence
2.
Int J STD AIDS ; 33(4): 363-373, 2022 03.
Article in English | MEDLINE | ID: mdl-35118929

ABSTRACT

BACKGROUND: In Mexico, the number of people living with HIV (PLWH) receiving antiretroviral therapy (ART) has increased in the last 20 years. The elimination of a CD4 threshold to initiate publicly funded ART was a major policy implemented in 2014. The study objective was to assess the determinants of Virologic Failure (VF) in Mexican PLWH on first-line ART between 2008 and 2017 and to evaluate the effects of changes following the 2014 policy. METHODS: A 10-year patient-level data analysis was conducted using the Mexican SALVAR database. The main outcome was the proportion of PLWH with VF. A multivariable logistic regression was conducted to identify the association between covariates and VF before and after the 2014 policy implementation. RESULTS: We found a lower proportion of people with VF in 2014-2017 compared with 2008-2013 (50% vs 33%, p<0.001). The multivariable analysis showed a reduction in the odds of virologic failure after 2014 (Odds ratio: 0.50 [95% CI: 0.48-0.51]). Place of treatment and level of deprivation were significant predictors of VF in during 2014-2017, but not before. CONCLUSION: This study indicates that, by lowering threshold levels of CD4 required for treatment initiation in Mexico, a higher number of PLWH initiated treatment during 2014-2017, compared to 2008-2013 and the odds of VF were reduced.


Subject(s)
Anti-HIV Agents , HIV Infections , Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/epidemiology , Humans , Mexico/epidemiology , Surveys and Questionnaires , Treatment Failure , Viral Load
3.
AIDS Res Ther ; 18(1): 84, 2021 11 13.
Article in English | MEDLINE | ID: mdl-34774077

ABSTRACT

BACKGROUND: In 2007-2012 the Mexican government launched the National HIV program and there was a major change in HIV policies implemented in 2013-2018, when efforts focused on prevention, increase in early diagnosis and timely treatment. Still, late HIV diagnosis is a major concern in Mexico due to its association with the development of AIDS development and mortality. Thus, the objectives of this study were to identify the determinants of late HIV diagnosis (i.e. CD4 count less than 200 cells/mm3) in Mexico from 2008 to 2017 and to evaluate the impact of the 2013-2017 National HIV program. METHODS: Using patient level data from the SALVAR database, which includes 64% of the population receiving HIV care in Mexico, an adjusted logistic model was conducted. Main study outcomes were HIV late diagnosis which was defined as CD4 count less than 200 cells/mm3 at diagnosis. RESULTS: The study included 106,830 individuals newly diagnosed with HIV and treated in Mexican public health facilities between 2008 and 2017 (mean age: 33 years old, 80% male). HIV late diagnosis decreased from 45 to 43% (P < 0.001) between 2008 and 2012 and 2013-2017 (i.e. before and after the implementation of the 2013-2017 policy). Multivariable logistic regressions indicated that being diagnosed between 2013 and 2017 (odds ratio [OR] = 0.96 [95% Confidence interval [CI] [0.93, 0.98]) or in health facilities specialized in HIV care (OR = 0.64 [95% CI 0.60, 0.69]) was associated with early diagnosis. Being male, older than 29 years old, diagnosed in Central East, the South region of Mexico or in high-marginalized locality increased the odds of a late diagnosis. CONCLUSIONS: The results of this study indicate that the 2013-2017 National HIV program in Mexico has been marginally successful in decreasing the proportion of individuals with late HIV diagnosis in Mexico. We identified several predictors of late diagnosis which could help establishing health policies. The main determinants for late diagnosis were being male, older than 29 years old, and being diagnosed in a Hospital or National Institute.


Subject(s)
HIV Infections , Adult , CD4 Lymphocyte Count , Delayed Diagnosis , Early Diagnosis , Female , HIV Infections/diagnosis , HIV Infections/drug therapy , HIV Infections/epidemiology , Humans , Male , Mexico/epidemiology
4.
Clinicoecon Outcomes Res ; 11: 325-333, 2019.
Article in English | MEDLINE | ID: mdl-31190925

ABSTRACT

Introduction: Electronic referral (eReferral) systems have been designed with the dual purpose of decreasing wait times and improving workflow efficiency. Evidence about the clinical and economic value enabled through the use of eReferral systems is limited. Our objective was to review the evidence base for the effectiveness and cost-effectiveness of eReferral systems. This review is part of a bigger project to inform the economic benefits of a regional eReferral implementation program. Material and methods: A systematic search was conducted to capture the available literature on the effectiveness and cost-effectiveness of eReferral system interventions. Evaluation of eReferral system for cost or outcome(s) were included. Strictly e-consultation systems were excluded. We only included publications in English. Results: We found 274 citations. After removing duplicates and conducting levels one and two screenings, nine publications qualified. Results were divided into four categories: cost or cost-effectiveness analysis, changes in workflow efficiency, the quantity of referrals, and the quality of referrals. A full economic evaluation, conducted in Denmark, found that an eReferral system was cost-effective compared with a paper-based referral system. Of the other eight studies, three demonstrated positive changes in referral processing; two evaluated changes in the quality of the referrals, and three evaluated if the eReferral system increased the quantity of referrals. Discussion: The evidence base on the effectiveness of eReferral systems to improve communication between primary care and specialists and to decrease wait times is positive but limited. Economic evaluations are needed to examine the clinical and economic value of eReferral systems in health care.

SELECTION OF CITATIONS
SEARCH DETAIL
...